ArticleDiabetes & metabolism journal2026
The Concurrent Challenges of Sarcopenia and Frailty: A 5-Year Mortality Risk Evaluation in Geriatric Patients with Type 2 Diabetes Mellitus.
Article in Diabetes & metabolism journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mitochondrial Proteostasis Links Diabetes and Sarcopenia: Cross-Scale Convergence from Experimental Models to Human Multi-Omics.Diabetes & metabolism journal · 2026Review
- Sarcopenia and Frailty in Type 2 Diabetes Mellitus: An Overlooked Challenge.Diabetes & metabolism journal · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgruoundType 2 diabetes mellitus (T2DM) is common among older adults and may increase the risk of sarcopenia and frailty. This study evaluated the impact of sarcopenia and frailty on 5-year mortality in older adults with T2DM.
methodsWe assessed a cohort study of 447 adults with T2DM who were more than 60 years old. Following the guidelines set by the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), we used bioelectrical impedance analysis to measure muscle mass and a handgrip dynamometer to measure muscle strength. We assessed frailty using the Fatigue, Resistance, Ambulation, Illnesses, and Loss of Weight (FRAIL) Scale. We categorised the patients into four groups: isolated sarcopenia, isolated frailty, both conditions (sarcopenia and frailty), or neither.
resultsThe median age of the patients was 69 years, and 71.6% were female. Isolated sarcopenia was present in 11.0% of patients, isolated frailty in 22.4%, and both sarcopenia and frailty in 9.8%. After adjustment for age, sex, comorbidities, activities of daily living, glycemic control, and nutritional status, sarcopenia and frailty were significantly associated with an increased risk of 5-year mortality. Isolated frailty also significantly predicted mortality (hazard ratio, 2.59; 95% confidence interval, 1.34 to 5.03; P=0.005).
conclusionSarcopenia and frailty were significant predictors of increased mortality risk in older adults with T2DM. Coexisting sarcopenia and frailty posed the highest risk. Early identification and targeted interventions for these conditions in older patients with T2DM are crucial to improving outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.